Y-27632 dihydrochloride: Selective ROCK1/2 Inhibitor for Cell Signaling Studies

Executive Summary: Y-27632 dihydrochloride is a potent and selective inhibitor of Rho-associated protein kinases ROCK1 and ROCK2, with IC₅₀ values of 140 nM and 300 nM, respectively (APExBIO). It exhibits >200-fold selectivity over off-target kinases such as PKC, cAMP-dependent protein kinase, MLCK, and PAK (APExBIO). Y-27632 disrupts Rho-mediated stress fiber formation and modulates cell proliferation, especially supporting stem cell viability in vitro (Ni et al. 2022). The compound is highly soluble in DMSO, ethanol, and water under standard laboratory conditions. It is used in translational research to study cell proliferation, cytoskeletal dynamics, and tumor invasion (UO126.com).

Biological Rationale

Rho-associated coiled-coil containing protein kinases (ROCK1 and ROCK2) are serine/threonine kinases that act downstream of the small GTPase RhoA. These kinases regulate actin cytoskeleton organization, smooth muscle contraction, cell proliferation, and apoptosis (Ni et al. 2022). Dysregulated Rho/ROCK signaling is implicated in cancer, cardiovascular disorders, neural development, and stem cell biology. In pluripotent stem cell (PSC) cultures, inhibition of ROCK pathway by agents such as Y-27632 enhances survival after dissociation and supports maintenance of pluripotency markers (Ni et al. 2022).

Mechanism of Action of Y-27632 dihydrochloride

Y-27632 dihydrochloride is a small-molecule inhibitor targeting the catalytic domains of ROCK1 and ROCK2. Its mode of action involves ATP-competitive inhibition, thereby blocking phosphorylation of downstream substrates necessary for actin stress fiber formation and focal adhesion assembly. Y-27632 inhibits ROCK1 with an IC₅₀ of approximately 140 nM and ROCK2 with a Ki of 300 nM (APExBIO). The compound demonstrates >200-fold selectivity for ROCK kinases over other tested kinases, including PKC, PKA, MLCK, and PAK, minimizing off-target effects (APExBIO). By abrogating ROCK activity, Y-27632 impairs Rho-mediated cytoskeletal dynamics, blocks cell cycle transition from G1 to S phase, and interferes with cytokinesis (PD-L1.com; extends mechanistic insights beyond this article by emphasizing translational applications).

Evidence & Benchmarks

• Y-27632 enhances survival and pluripotency marker expression in human induced pluripotent stem cells (iPSCs) derived from patients with schizophrenia and bipolar disorder (Ni et al. 2022, DOI).
• Selective inhibition of ROCK1 and ROCK2 by Y-27632 is supported by enzymatic assays reporting IC₅₀ values of 140 nM and 300 nM, respectively (APExBIO, product page).
• Y-27632 is soluble at ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, and ≥52.9 mg/mL in water at room temperature (APExBIO, specifications).
• In vitro, Y-27632 reduces proliferation of prostatic smooth muscle cells in a concentration-dependent manner (APExBIO, datasheet).
• In vivo, Y-27632 diminishes tumor invasion and metastasis in mouse xenograft models (APExBIO, reference).
• All iPSC lines treated with Y-27632 retained the ability to differentiate into all three germ layers, confirmed by teratoma assay (Ni et al. 2022, DOI).

Applications, Limits & Misconceptions

Y-27632 dihydrochloride is widely used in cell biology, cancer research, and stem cell workflows (UO126.com; this article updates the protocol specificity for disease-relevant models). Major applications include:

• Enhancing survival of dissociated PSCs and improving single-cell cloning efficiency.
• Studying Rho/ROCK-mediated actin cytoskeleton dynamics in cell migration and invasion assays (PX-12.com; this article adds recent disease models for psychiatric disorders).
• Suppressing smooth muscle cell proliferation in prostate and vascular research.
• Reducing tumor cell invasion, metastasis, and pathologic angiogenesis in preclinical cancer models.
• Modulating cytokinesis and cell cycle progression for mechanistic studies.

Common Pitfalls or Misconceptions

• Y-27632 does not induce pluripotency; it supports survival after dissociation but does not replace reprogramming factors (Ni et al. 2022).
• It is not effective against non-ROCK kinases at standard working concentrations; use alternative inhibitors for PKC or MLCK.
• Prolonged exposure (>48–72 hours) can affect differentiation potential; protocol-specific optimization is required.
• Solubility is temperature- and solvent-dependent; always verify clarity before use (MHC Class II Antigen; this article clarifies solvent selection and storage).
• It should not be used as a universal anti-apoptotic agent; mechanism is ROCK-specific.

Workflow Integration & Parameters

For laboratory use, Y-27632 dihydrochloride (SKU A3008, see A3008 kit) is supplied as a solid. It is soluble at ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, and ≥52.9 mg/mL in water. Gentle warming (37°C) or sonication may improve dissolution. Stock solutions should be stored below -20°C for short-term use; avoid long-term solution storage to prevent degradation. For in vitro stem cell applications, typical working concentrations range from 5–50 μM. In cancer or cytoskeletal assays, titration is recommended for optimal specificity (Molecular Beacon; this article provides updated storage and preparation details for reproducibility). Batch-to-batch consistency is maintained by APExBIO, ensuring reliability across research studies. For reproducibility, always document solvent, concentration, and exposure time. Use appropriate controls to distinguish ROCK-dependent from unrelated effects.

Conclusion & Outlook

Y-27632 dihydrochloride remains the gold standard for selective inhibition of ROCK1 and ROCK2. Its high selectivity, robust solubility, and established efficacy in stem cell, cancer, and cytoskeletal studies are supported by peer-reviewed evidence (Ni et al. 2022). As new disease models—such as patient-derived iPSC lines for psychiatric disorders—emerge, Y-27632 will continue to be integral to mechanistic, translational, and therapeutic research. The A3008 kit from APExBIO offers validated quality and documentation for advanced Rho/ROCK pathway studies (product page).